DBV Technologies S.A.

DBVTF ·Healthcare, Drug Manufacturers - General
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-146.9M $-113.9M $72.7M $96.3M $-97.8M $-159.6M $-172.0M
Depreciation & Amortization $3.0M $2.7M $3.6M
Depreciation $3.6M $2.7M $4.4M $4.4M
Amortization
Stock-Based Compensation $5.4M $4.6M $6.0M $5.0M $3.1M $-1.1M $17.2M
Net Cash from Operating Activities $-121.2M $-104.5M $-79.7M $-55.7M $-108.2M $-165.6M $-148.3M
Investing Activities
Capital Expenditures $532.0K $2.3M $677.0K $754.0K $910.0K $2.8M $5.6M
Business Acquisitions
Net Cash from Investing Activities $-1.4M $-757.0K $-808.0K $-100.0K $-433.0K $-2.9M $-5.7M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $276.2M $587.0K $6.8M $194.1M $274.0K $149.5M $207.6M
Net Change in Cash $161.7M $-108.9M $-67.8M $131.9M $-119.1M $3.1M
Free Cash Flow $-121.7M $-106.8M $-80.3M $-56.4M $-109.2M $-168.4M $-153.9M